Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M

INTERPACE BIOSCIENCES, INC.

2024-Q2 EPS reported $0.58 revenue$22,314,000

Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.
Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.
Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).
Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.
Gross profit margin stable at 62%; operating expenses down ~14% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.